United States $10 Billion Generic Injectables Mark

Dublin, Nov. 24, 2017 (GLOBE NEWSWIRE) -- The "US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report has been added to Research and Markets' offering. The market is projected to reach a value of more than US$ 16 Billion by 2022, growing at a CAGR of around 8% during 2017-2022. The US generic injectables market reached a value of US$ 10 Billion in 2016, exhibiting a CAGR of more than 9% during 2009-2016. The market growth can be attributed to the low cost of these drugs as compared to their branded counterparts. Moreover, as there is limited price erosion and low competition in the market, the profit margins are significantly higher than commoditised generics. Generic injectables are widely used in the treatment of various chronic diseases such as cancer, diabetes, cardiovascular diseases, respiratory diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, etc. In the United States, these drugs form an important part of the public healthcare system and contribute in significant savings for the patients and healthcare providers. Over the next few years, the market is expected to be driven by a number of favourable factors. The cases of chronic diseases have been increasing on account of ageing population, sedentary lifestyles and poor eating habits. This has resulted in a heightened demand for generic injectables. Furthermore, the drug shortages in the country coupled with speedy approvals by the USFDA are expected to boost the manufacturing of these drugs. Additionally, the patent expiry of a large number of branded injectable drugs is expected to support the market growth. The report has segmented the market on the basis of therapeutic area and covers oncology, anaesthesia, anti-infectives, parenteral nutrition, cardiovascular diseases, etc. Among these, oncology generic injectables represent the largest segment. The report has further analysed the various containers used for generic injectables including vials, premix, prefilled syringes and ampoules. On the basis of distribution channels, the report finds that hospitals dominate the market, accounting for the majority of the share. The report has also examined the competitive landscape of the market and provides the profiles of the key players operative in it. Some the major players are Hospira, Hikma, App, Sagent, Sandoz and Henry Shein, Inc. Key Topics Covered: 1 Preface 2 Scope and Methodology 2.1 Objectives of the study 2.2 Stakeholders 2.3 Data Sources 2.4 Market Estimation 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Generic Drug Industry 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Country 5.4 Market Forecast 6 US Generic Drug Industry 6.1 Market Overview 6.2 Market Performance 6.3 Market Forecast 7 US Generic Drug Industry - Drug Delivery Systems 7.1 Orals 7.2 Injectables 7.3 Dermal/Topical 7.4 Inhalers 8 Global Generic Injectables Industry 8.1 Market Overview 8.2 Market Performance 8.3 Market Breakup by Region 8.4 Market Breakup by Therapeutic Area 8.5 Market Breakup by Containers 8.6 Market Breakup by Distribution Channel 8.7 Market Share of Key Players 8.8 Market Forecast 9 US Generic Injectables Industry 9.1 Market Overview 9.2 Market Performance 9.3 Market by Therapeutic Area 9.4 Market by Containers 9.5 Market by Distribution Channel 9.6 Market Share of Key Players 9.7 Market Forecast 9.8 SWOT Analysis 9.9 Value Chain Analysis 9.10 Porters Five Forces Analysis 9.11 Key Success and Risk Factors 10 Market by Therapeutic Area 10.1 Oncology 10.2 Anaesthesia 10.3 Anti-infectives 10.4 Parenteral Nutrition 10.5 Cardiovascular 11 Market by Containers 11.1 Vials 11.2 Ampoules 11.3 Premix 11.4 Prefilled Syringes 12 Market by Distribution Channel 12.1 Hospitals 12.2 Retail Pharmacy 13 US Generic Injectable Market: Competitive Landscape 13.1 Competitive Structure 13.2 Market Breakup by Key Players 14 Generic Injectables Manufacturing Process 14.1 Product Overview 14.2 Detailed Process Flow 14.3 Various Types of Unit Operations Involved 14.4 Mass Balance and Raw Material Requirements 15 Project Details, Requirements and Costs Involved 15.1 Land, Location and Site Development 15.2 Construction Requirements 15.3 Machinery Requirements 15.4 Machinery Pictures 15.5 Raw Materials Requirements 15.6 Raw Material and Final Product Pictures 15.7 Packaging Requirements 15.8 Transportation Requirements 15.9 Product Pricing and Margins Across Various Levels of the Supply Chain 16 Key Players Profiles

• Hospira
• Hikma
• App
• Sagent
• Sandoz and Henry Shein, Inc

For more information about this report visit https://www.researchandmarkets.com/research/s...us_generic

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Infusions and Injectables